INS and Hypoglycemia: In Table 3, using three times Taiwan’s GDP as the WTP threshold (US$77,679), the base-case analysis indicated that using a GLP-1RA versus insulin was cost-effective for preventing one case with all-cause mortality or hospitalized hypoglycemia from the payer perspective, and cost-saving from the healthcare sector perspective.